Johnson & Johnson has announced encouraging results from its pivotal Phase 2/3 ENERGY study evaluating IMAAVY (nipocalimab-aahu) in patients with warm autoimmune hemolytic anemia (wAIHA), a rare autoimmune blood disorder that currently has no FDA-approved therapies. The findings suggest that the investigational treatment could offer a much-needed targeted option for patients struggling with chronic anemia and severe fatigue.

Chronic pancreatitis (CP) is often recognized for the severe abdominal pain it causes, but new research from Mayo Clinic suggests that the disease affects far more than pain alone. The study reveals that CP significantly impacts mobility, self-care, routine activities, mental well-being, and overall quality of life, highlighting the need for a more comprehensive approach to patient care.
The findings were first made available online on August 27, 2025, and later published in the Journal of Pancreatology (Volume 9, Issue 1) on March 30, 2026.

Researchers from Keio University School of Medicine in Japan have identified a previously unknown immune mechanism that may be responsible for sustaining the chronic autoimmune response seen in Sjögren’s disease. The discovery sheds new light on how the disease progresses and could open the door to targeted treatments that avoid the broad immune suppression associated with current therapies.